Latest news
Loading news…
Sangamo Therapeutics
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Richmond, California, United States Founded 1995 251-500 employees For Profit
Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Sangamo Therapeutics on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
Sangamo Therapeutics was acquired by Eli Lilly in 2026 for $50M.
Total Funding
$594.1M
Funding Rounds
10
Last Funding
Acquisitions
2
Monthly Visits
Contacts
383
Ticker
SGMO
NASDAQ
Patents
296
10 trademarks
About Sangamo Therapeutics
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Public
- Ticker
- SGMO
- Exchange
- NASDAQ
- IPO date
- Apr 6, 2000
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 15
- Active products
- 28
- Patents granted
- 296
- Trademarks
- 10
- Top patent class
- Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering
- IT spend
- $2.53M
Company Info
- Founded
- 1995
- Employees
- 251-500
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 337
- HQ
- Richmond, California, United States
- Region
- San Francisco Bay Area, West Coast, Western US
- Exit date
- Apr 6, 2000
Signals & Scores
- Heat score
- High
- Growth score
- Low
- Trend (7d)
- -0.4
- Trend (30d)
- 7.6
- Trend (90d)
- 8.1
- Last leadership hire
- Feb 3, 2026
- Last layoff mention
- Jun 23, 2026
Sangamo Therapeutics Funding Rounds
10 results
Upgrade to Pro to view this datasetUpgrade
| Organization Name | Funding Type | Lead Investor Names | Org Hq Country | ||
|---|---|---|---|---|---|
1–5 of 10Show
Page 1 / 2
Sangamo Therapeutics Acquisitions
2 results
| Acquiree Name | Acquirer Name | Acquiree Industries | Acquiree Hq Country | ||
|---|---|---|---|---|---|
| TxCell | $84.35M | 2018-07-23 | Sangamo Therapeutics | BiotechnologyPharmaceuticalTherapeutics | France |
| Ceregene | — | 2013-08-26 | Sangamo Therapeutics | BiotechnologyHealth DiagnosticsPharmaceutical | United States |
1–2 of 2Show
Page 1 / 1
Sangamo Therapeutics Key People
Executive Vice President & Chief Business Officer
Chief Quality Officer
Interim Chief Financial Officer
CFO
Chief Scientific Officer
Vice President of Bioinformatics
Director, Clinical Sciences
Chief Executive Officer
383
professional contacts at Sangamo Therapeutics
Contact execs at Sangamo Therapeutics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
Recent News related to Sangamo Therapeutics
Loading news…
FAQs about Sangamo Therapeutics
People who checked this page also checked these
Sectors Sangamo Therapeutics invests & acquires in
Browse the full Acquirezy directory.